Literature DB >> 28095714

Disease-related and drug-induced skin manifestations in inflammatory bowel disease.

Pieter Hindryckx1, Gregor Novak2, Antonio Costanzo3, Silvio Danese4,5.   

Abstract

INTRODUCTION: Skin manifestations are common in patients with inflammatory bowel diseases (IBD) and can be part of a concomitant illness with a shared genetic background, an extra-intestinal manifestation of the disease, or a drug side-effect. Areas covered: We provide a practical overview of the epidemiology, pathogenesis, diagnosis, therapeutic approach and prognosis of the most frequent disease-related and drug-induced cutaneous manifestations in IBD, illustrated by cases encountered in our clinical practice. Among the most frequently encountered IBD-related lesions are erythema nodosum, pyoderma gangrenosum and Sweet's syndrome. Common skin manifestations with a strong association to TNF antagonists are local injection site reactions, psoriasiform lesions, cutaneous infections, vasculitides and lupus-like syndromes. In addition, we discuss the relation of thiopurines and TNF antagonists with the risk of skin cancer. Expert commentary: We hope this review will help caretakers involved in the management of IBD patients to recognize the lesions and to manage them in close collaboration with a dedicated dermatologist.

Entities:  

Keywords:  Skin lesions; cutaneous; drug-induced; extra-intestinal; inflammatory bowel disease

Mesh:

Substances:

Year:  2017        PMID: 28095714     DOI: 10.1080/17474124.2017.1283985

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  9 in total

1.  Sweet's Syndrome as Manifestation of Active Ulcerative Colitis.

Authors:  Mario Bento-Miranda; David N Perdigoto; Sofia Mendes; Francisco Portela
Journal:  GE Port J Gastroenterol       Date:  2019-08-06

Review 2.  Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment.

Authors:  Jianrong Shi; Wangqian Ma; Huifang Tang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

3.  Dissecting Cellulitis of the Scalp: A Rare Dermatological Manifestation of Crohn's Disease.

Authors:  Taseen A Syed; Zain Ul Abideen Asad; George Salem; Kanika Garg; Erin Rubin; Nelson Agudelo
Journal:  ACG Case Rep J       Date:  2018-01-31

4.  Postsurgical Pyoderma Gangrenosum Following Carpal Tunnel Release: A Rare Disease Following a Common Surgery.

Authors:  Michael R Ruebhausen; Shaun D Mendenhall; Michael W Neumeister; Nada N Berry
Journal:  Eplasty       Date:  2017-03-21

5.  Leukocytoclastic vasculitis as a rare dermatologic manifestation of Crohn's disease mimicking cellulitis: a case report.

Authors:  Meredith Buck; Igor Dumic; Wendy McDermott; Charles Nordstrom; Samarth Dawan; Andrew Virata; Scott Martin; Ann Hudson; Tamara Milovanovic; Terri Nordin
Journal:  BMC Gastroenterol       Date:  2020-07-29       Impact factor: 3.067

6.  The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Teng Hung; Puo-Hsien Le; Chia-Jung Kuo; Yu-Chuan Tang; Meng-Jiun Chiou; Cheng-Tang Chiu; Chang-Fu Kuo; Yu-Huei Huang
Journal:  J Clin Med       Date:  2021-03-22       Impact factor: 4.241

7.  Sweet's Syndrome: A Case Report of a Rare Extraintestinal Manifestation of Ulcerative Colitis.

Authors:  Maria Inês Santos; Ana Mestre; Natália Teixeira; Cátia Correia; Marisa Brochado
Journal:  Cureus       Date:  2022-03-08

Review 8.  The Skin in Celiac Disease Patients: The Other Side of the Coin.

Authors:  Ludovico Abenavoli; Stefano Dastoli; Luigi Bennardo; Luigi Boccuto; Maria Passante; Martina Silvestri; Ilaria Proietti; Concetta Potenza; Francesco Luzza; Steven Paul Nisticò
Journal:  Medicina (Kaunas)       Date:  2019-09-09       Impact factor: 2.430

Review 9.  Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review.

Authors:  Jo L W Lambert; Sofie De Schepper; Reinhart Speeckaert
Journal:  J Clin Med       Date:  2021-03-03       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.